Skip to content

Should we use remifentanil in every dose and every case?

Is remifentanil proper for all anesthetic procedure?

Original Research doi:10.4328/JCAM.5942 Published: January 1, 2019

Authors

Affiliations

1Department of Anesthesiology and Reanimation, Erzurum Regional Training and Research Hospital, Erzurum, Türkiye.

2Department of Pharmacology and Toxicology, Faculty of Veterinary Science, Atatürk University, Erzurum, Türkiye.

Corresponding Author

Abstract

AimWe widely use remifentanil as a pain killer in all cases that need surgery such as: broken bone, intestine, brain disease, organ transplantation. But we need to apply any of opioid analgesics according to the surgery type. The aim of the study is to determine neurotoxic or neuroprotective effects of different remifentanil doses in glutamate induced toxicity model in cerebellum cell culture.
MethodCerebellum neurons were obtained from pupil of newborn Sprague dawley rat. Glutamate (10⁻⁵ mM) was added to all culture dishes except negative control group. Remifentanil was added in three different doses for 24 hours, and then evaluation was done by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Total Antioxidant Capacity (TAC), Total Oxidant Status (TOS) and Flow cytometry (Annexin V- apoptosis marker).
ResultsOur data shows the highest and the lowest viability obtained from low and high remifentanil dose around %91 and %75 respectively. TAC and TOS results have correlation with MTT results. TAC capacity in remifentanil 0,2 mM group shows nearest to control group value.
ConclusionAccording to our result, remifentanil has potential to decrease toxicity level of glutamate and increases cell viability ratio.

Keywords

remifentanil cerebellum glutamate neurotoxicity total oxidant status

Declarations

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

About This Article

Received:
June 21, 2018
Accepted:
July 25, 2018
Published Online:
July 29, 2018
Printed:
January 1, 2019